

April 2021

Association Of Vitamin D Receptor, Interleukin7 Receptor Alpha Gene Polymorphisms With The Risk Of Multiple Sclerosis

Ansam Mokbel Zayed

Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt, nesmazayed91@gmail.com

Amaal Elsayed Shehata

Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt, amalelmalt@yahoo.com

Tarek Abd Al Rahman Gouda

Neurology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt, t-gouda@hotmail.com

Hanim Magdy Abd elnour

Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt, hanemmagdy1982@gmail.com

Follow this and additional works at: <https://digitalcommons.aaru.edu.jo/zumj>

Recommended Citation

Zayed, Ansam Mokbel; Shehata, Amaal Elsayed; Gouda, Tarek Abd Al Rahman; and Abd elnour, Hanim Magdy (2021) "Association Of Vitamin D Receptor, Interleukin7 Receptor Alpha Gene Polymorphisms With The Risk Of Multiple Sclerosis," *Zagazig University Medical Journal*: Vol. 27 : Iss. 1 , Article 35. Available at: <https://digitalcommons.aaru.edu.jo/zumj/vol27/iss1/35>

This Original Article is brought to you for free and open access by Arab Journals Platform. It has been accepted for inclusion in Zagazig University Medical Journal by an authorized editor. The journal is hosted on [Digital Commons](#), an Elsevier platform. For more information, please contact rakan@aar.edu.jo, marah@aar.edu.jo, u.murad@aar.edu.jo.



Manuscript ID ZUMJ-1906-1254 (R2)

DOI 10.21608/zumj.2019.13593.1254

ORIGINAL ARTICLE**Association of Vitamin D Receptor, Interleukin7 Receptor Alpha Gene Polymorphisms With The Risk Of Multiple Sclerosis**Ansam Mokbel Zayed El Desoky ^{1*}, Amaal El Sayed Shehata ¹;Tarek Abd Alrahman Gouda ²; Hanim Magdy Abdelnour ¹*1: Medical Biochemistry department, Faculty of Medicine, Zagazig university.**2: Neurology department, Faculty of Medicine, Zagazig university.****Corresponding author:**Ansam Mokbel Zayed El Desoky.
Demonstrator of Medical Biochemistry, Faculty of Medicine, Zagazig, Egypt.**E mail :**

nesmazayed91@gmail.com

Submit Date 2019-06-11

Revise Date 2019-07-02

Accept Date 2019-07-02

ABSTRACT

Background: Multiple sclerosis (MS) is a chronic autoimmune neurodegenerative disease with unknown definite etiology. Many factors have taken part in explanation of MS pathology including genetics and environmental factors. In this study we investigated the frequency of vitamin D receptor (VDR) gene (bsm1 and taq1) and interleukin 7 receptor alpha (IL7RA) gene single nucleotide polymorphisms (SNPs) and their association with the risk of MS.

Methods: a case control study was performed on two groups. MS group with 63 MS patients diagnosed according to McDonald criteria for MS diagnosis and the control group of 63 apparently healthy individuals not having MS. Blood was collected and DNA was extracted. DNA was amplified using Polymerase chain reaction. Then analysis for VDR SNPs (bsm1 and taq1) by restriction fragment length polymorphism assay. Amplification refractory mutation system technique was carried out to evaluate IL7RA SNP.

Results: we found that there was statistically significant difference in Bsm1 genotyping between case and control groups ($p=0.02$). As for IL7RA genotype frequency between MS patients and controls there was statistically significant difference ($p=0.004$). And lastly Taq1 genotyping revealed no statistically significant association with MS ($p=0.5$).

Conclusion: we conclude that VDR (Bsm1) and IL7RA SNPs are related to MS pathogenesis while VDR (Taq1) SNP is not a risk factor for MS in an Egyptian sample.

Key words: Multiple sclerosis, Vitamin D receptor, Interleukin 7 Receptor, gene polymorphism

INTRODUCTION

Multiple sclerosis (MS) is a chronic disease characterized by neuroinflammation and axonal demyelination in the central nervous system. The disease usually

affects females in reproductive age. Clinically variable neurologic presentations are usually present according to the type of demyelinated nerve either: motor sensory or autonomic [1]. In 2015, about 18,900 people died from MS, up

from 12,000 in 1990[2]. The etiology of MS is unknown. Genetics and environment share in MS pathogenesis. HLA class II haplotype HLA-DRB 1501 was the first identified risk locus to be strongly associated to MS [3]. Additional 200 non MHC different MS risk loci were further identified[4]. The environmental risk factors for MS include smoking, Epstein–Barr virus (EBV) infection, obesity, vitamin D deficiency, and working night shifts. While oral tobacco, excess coffee drinking, alcohol, and cytomegalovirus (CMV) infection were found to lower the disease risk [5].

In the past decade, much attention has been given to vitamin D and its role in MS. Vitamin D is important for bone and mineral homeostasis and has immunoregulatory and anti-inflammatory functions[6]. Vitamin D mediates its function through vitamin D receptor (VDR) which is expressed on the surface of different immune cells [7]. Many studies on VDR single nucleotide polymorphisms (SNPs) have reported four SNPs of possible disease association; three at the 3' end of the VDR gene (TaqI, BsmI, ApaI) and one at the 5'end (FokI)[8].

Interleukin-7 receptor alpha chain (IL-7Ra) or (CD127) located on chromosome 5P13 was found to be the first non-major histocompatibility complex (non-MHC) susceptibility locus for MS [9]. Interleukin-7 binds the IL7R common gamma chain (namely CD132) and its alpha chain (namely IL7RA or CD127), forming the signaling complex in the IL7 pathway. The IL7/IL7R interaction is essential for the survival, proliferation, and differentiation of T-cells, especially CD4+ T-cells, which is present in the inflammatory lesions of multiple sclerosis patients[10].

METHODS

This is a case control study which included 63 MS patients diagnosed according to McDonald criteria for MS diagnosis and 63 apparently healthy individuals without MS. They didn't have any disease or administrate any drugs that may influence the current study.

Written informed consent was obtained from all participants and the study was approved by the research ethical committee of Faculty of Medicine, Zagazig University. The work has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for studies involving humans. Socio-demographic characteristics of the studied groups are shown in [table 1] and [figure 1]. Clinical data findings of the studied groups are shown in [table 2]

Collection of samples:

Peripheral venous blood samples were taken and dispensed into 3 ml tubes containing 5.4 mg of ethylene diamine tetra acetic acid (EDTA) then they were stored at -20°C for DNA extraction.

DNA Extraction

Genomic DNA was extracted from EDTA anticoagulated peripheral blood leucocytes according to the manufacturer's instructions using G-spin™ Total DNA Extraction Mini Kit provided by iNtRON Biotechnology, Korea. Extracted DNA was stored at -20°C for further use.

Purity of DNA could be detected by measuring A260 (the absorbance at 260 nm) to A280 ratio. Pure double stranded DNA sample is assumed to have an A260/ A280 ratio ranging from 1.7 to 1.9. ⁽¹¹⁾

Detection of VDR (BsmI and Taq I) polymorphism by polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP):

Components of the 20 µl Rxn PCR reaction mixture:

2X PCR Master mix Solution (i-Taq™) 10 µl
 Template DNA 2 µl
 Primer (Forward : 10 pmol/ µl) 1 µl
 Primer (Reverse : 10 pmol/ µl) 1 µl
 Distilled Water 6 µl

Primer sequences (5' to 3'):

1-For BsmI:

BsmI Forward:
 CAACCAAGACTACAAGTACCGCGTCAG
 TGA

BsmI Reverse:

AACCAGCGGGAAGAGGTCAAGGG

2- For Taq I:

Taq I Forward:

CAGAGCATGGACAGGGAGCAAG

Taq I Reverse:

GCAACTCCTCATGGCTGAGGTCTCA

PCR Conditioning:

PCR included cycles of: initial denaturation at 94°C for 4 min then 30 cycles of denaturation at 94°C for 30 sec, annealing at 58°C for 30 sec for the BsmI SNP (59°C for 30 sec for the Taq I SNP), extension at 72°C for 1 min, and final extension at 72° C for 5 min. AG Eppendorf. Inc. Mastercycler, Hamburg. Germany was used for amplification reaction.

RFLP was performed using BsmI and Taq I restriction enzymes purchased from Thermo Fisher Scientific, USA.

The digested PCR products were subjected to gel electrophoresis, stained with ethidium bromide and visualized by UV transilluminator. The BsmI restriction polymorphism showed two possible alleles, allele B and b with three available genotypes: BB, Bb, bb.

DNA yields a single 870 bp band in normal homozygous (BB) with absence of restriction site while in presence of the restriction site two bands (700&170 bp) are obtained in case of bb genotype and three bands (870,700,170 bp) in the heterozygous form (Bb).

The TaqI restriction polymorphism has two possible alleles, allele T and t with three available genotypes: TT, Tt, tt.

Following digestion of the PCR product with TaqI restriction enzyme, 495 and 245 bp fragments appeared in case of homozygous genotype *TT* indicating absence of restriction site, while in presence of the restriction site three fragments (290, 245 and 205 bp) are obtained in case of *tt* genotype and four fragments (495, 290, 245 and 205 bp) in the heterozygous form (*Tt*).

Detection of IL7RA gene polymorphism:

Amplification-refractory mutation system (ARMS) was performed to detect IL7RA gene polymorphism.

Four primers were used, two were for

internal control and two specific for T or C allele.

The sequence specific forward primer:

5'-AAGAAGGGAAGAGAGCATTGG-3',

The sequence specific reverse primers were:

5'-GAAAAAACTCAAATGCTGATGG-3'

(for C allele)

and

5'-AGAAAAAACTCAAATGCTGATGA-3'

(for T allele)

And the last reverse primer for internal control was:

5'-TTACTTTGGGGACAGCGTTT-3'.

Components of the 20 µl Rxn PCR reaction mixture:

2X PCR Master mix Solution (i-Taq™) 10 µl

Template DNA 2 µl

Forward Primer 1 µl

Reverse Primer for C allele 1 µl (in case of T allele amplification 1 µl of reverse primer for T allele was used instead)

Reverse Primer for internal control 1 µl

Distilled Water 5 µl

PCR Conditioning:

PCR included cycles of: denaturation of 94° C for 5 min followed by 35 cycles of denaturation at 94° C for 30 s, annealing at 62° C for 30 s and extension at 72° C for 30 s. The final extension step was at 72° C for 5 min.

The PCR products were subjected to 1.5 % gel electrophoresis, stained with ethidium bromide and visualized by UV transilluminator.

Statistical analysis

Data were analyzed using SPSS version 23 for data processing. Data were expressed as number and percentage for qualitative variables and mean + standard deviation (SD) for quantitative one. The level of significance was set at *P* value < 0.05.

RESULTS

There was statistically significant difference in BsmI genotyping between case and control groups (*p*=0.02), shown in [table 3] and [figure 2]. Regarding IL7RA genotype frequency between MS patients and controls, there was statistically significant difference (*p*=0.004), shown in [table 5]. And lastly

TaqI genotyping revealed no statistically significant association with MS ($p=0.5$), shown in [table 4].

There was a statistically significant difference between MS patients and controls regarding allele frequencies of VDR (BsmI) polymorphism ($p=0.01$). Inheritance of b allele was associated with nearly 2 fold increase in the risk of MS. In control group, frequency for B allele was 78.6% and frequency for b allele was 21.4%. In MS group, frequency for B allele was 65.1% and frequency for b allele was 34.9%. Chi square (χ^2) was 5.7 and there was a significant association among the studied groups ($p=0.01$). Odds Ratio (95%CI) was 1.97(1.12-3.45).

There was a statistically significant difference between MS patients and controls regarding allele frequencies of IL7RA gene polymorphism ($p=0.001$). Inheritance of T

allele was associated with 2.68 fold increase in the risk of MS.

In control group, frequency for C allele was 83.3% and frequency for T allele was 16.7%. In MS group, frequency for C allele was 65.1% and frequency for T allele was 34.9%. Chi square (χ^2) was 10.9, $p=0.001$ and Odds Ratio (95%CI) was 2.86 (1.48-4.86).

In relation to allele frequency of VDR (TaqI) polymorphism, in control group, frequency for T allele was 67.5% and frequency for t allele was 32.5%. In MS group, frequency for T allele was 72.2% and frequency for t allele was 27.8%.

Chi square (χ^2) was 0.68 and there was a non significant association among the studied groups regarding allele frequencies of TaqI polymorphism ($p=0.41$) (>0.05). Odds Ratio (95%CI) was 0.79 (0.47-1.37).

Table 1. Comparing socio-demographic characteristics between MS and control groups

Variable	Case (63) mean \pm SD (Range) Median	Control (63) mean \pm SD (Range) median	t-test	p-value
Age	33.1 \pm 5.8 (19-44) 34	31.9 \pm 4.9 (19-44) 32	1.2	0.2
Variable	Case No(63) %	Control No(63) %	χ^2	p-value
Sex			0.04	0.8
Male	15 23.8%	14 22.2%		
Female	48 76.2%	49 77.8%		

Table 2. Comparing clinical data finding between MS and control groups

Variable	Case group		Control group		χ^2	p-value
	No(63)	%	No(63)	%		
Smoking					0.5	
No	51	81.0%	54	85.7%		0.4
Yes	12	19.0%	9	14.3%		
D.M					0.0	
No	45	71.4%	45	71.4%		1
Yes	18	28.6%	18	28.6%		
HTN					0.9	
No	47	74.6%	42	85.7%		0.4
Yes	16	25.4%	21	14.3%		

Table 3. Genotype frequency of VDR (BsmI) between studied groups

BsmI	MS group		Control group		χ^2	p-value
	No (63)	%	No (63)	%		
BB	30	47.6	38	60.3%	7.2	0.02*
Bb	22	34.9%	23	36.5%		
bb	11	17.5%	2	3.2%		

Table 4. Genotype frequency of VDR (TaqI) between studied groups

TaqI	MS group		Control group		χ^2	p-value
	No(63)	%	No(63)	%		
TT	29	46.0%	23	36.5%	1.2	0.5
Tt	33	52.4%	39	61.9%		
Tt	1	1.6%	1	1.6%		

Table 5. Genotype frequency of IL7RA between studied groups

IL7RA	MS group		Control group		χ^2	p-value
	No(63)	%	No(63)	%		
CC	27	42.9%	43	68.2%	10.8	0.004*
TT	8	12.7%	1	1.6%		
Ct	28	44.4%	19	30.2%		




Fig 1. Demographic characteristics of the studied groups




Fig 2. Distribution of frequency for VDR (BsmI) gene polymorphism in all studied groups.

DISCUSSION

Multiple sclerosis (MS) is a chronic neuroinflammatory disorder affecting the brain and spinal cord. More than two million individual around the world are distressed with MS mostly middle aged females. The disease represents a considerable cause of permanent disability in young adults[11].

The precise etiology of MS is still

indistinct and it is thought to result from interplay between genetics and environment. The first and the most associated locus to MS is the major histocompatibility complex (MHC) that alone can interpret about 10% of MS genetics[12].

Genome wide association studies (GWAS) have listed many risk alleles that are linked with higher incidence of MS and could

determine a genetic variant, located on chromosome X, was listed as MS risk allele. These loci can explain about 30% of MS pathogenesis[13].

Vitamin D which increases serum calcium level and regulates bone metabolism is now established to have immunomodulatory effects. It influences both cell mediated and humoral immune responses through distribution of its receptor among various immune cells. Vitamin D controls gene expression through its vitamin D responsive elements (VDRE) present on the DNA. It has been found that these VDRE are present in the active decondensed chromatin form in the immune cells compared to other body cells[14].

Concerning cell mediated immune response, active vitamin D acts mainly to suppress T cell proliferation. It inhibits both INF- γ producing Th1 cell and IL-17 producing Th17 cell which are associated with inflammation and autoimmunity. As a consequence immune response is shifted toward Th2 which antagonizes inflammation through production of IL-3, -4, -10. B cells proliferation is inhibited by vitamin D[15].

Regarding VDR gene polymorphisms (Bsm I), this study showed that Bsm I is associated with higher risk of MS ($p=0.02$). This finding was in agreement with[16-18]

On the other hand [19-20] have showed discordant results to this study and reported no association between VDR SNP (Bsm I) and the risk of MS.

As for the VDR gene Taq I polymorphism, this study failed to find an association between the Taq I polymorphism and the risk developing of MS ($p=0.5$). This was in line with [21-22]. Opposite to our finding, [23] reported a positive correlation between VDR (Taq I) SNP and MS risk.

This discrepancy of search results is due to variability in ethnicity and population genetic characteristics. MS has been reported to be polygenic disorder with multiple risk loci and interaction between these loci should be taken in consideration. Additionally

differences in sample size, research tools, clinical type and disease severity of MS in patients involved in a certain study can explain such discrepancy.

In relation to IL7RA gene polymorphism (rs6897932), our study suggested a positive correlation between IL7R T244I polymorphism (rs6897932) polymorphism and MS ($p=0.004$).

This result is concordant with [24] who performed a meta-analysis to evaluate the IL7RT244I polymorphism association to MS. They confirmed that the IL7R T244I polymorphism is associated with MS. They reported that T244I influences differential splicing of exon 6 and that the C allele at rs6897932 is associated with more exon skipping, production of soluble IL7RA and associated with higher probability of MS. While the T allele is associated with less exon skipping and a membrane bound IL7RA production.

Moreover, [25] submitted eleven case-control studies in a meta-analysis, and reported that the IL7RA T244 I gene polymorphism is a predisposing factor for MS. He also confirmed that the C allele is more relevant to MS risk while T allele is associated with low risk.

However, [26] didn't find any significant positive relation of rs6897932 SNP and pathogenesis of MS. They attributed these findings to differences in populations' genetics and the interaction of many genetic loci in developing MS.

CONCLUSION

We conclude that VDR SNP (Bsm1) is one of the risk factors that participate in MS pathogenesis. Moreover IL7RA SNP is strongly related to MS development while VDR (Taq1) SNP is not a precipitating factor of MS in an Egyptian sample.

REFERENCES

1. Ransohoff RM, Hafler DA and Lucchinetti, CF. Multiple sclerosis—a quiet revolution. *Nature Reviews Neurology*. 2015; 11 (3), 134-142.
2. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A et al. (2016). Global, regional, and national life expectancy, all-cause

- mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study. *The Lancet*. 2015; 388(10053), 1459-1544.
3. **Van Luijn, MM , Kreft KL , Jongasma ML, Mes SW, Wierenga-Wolf AF, van Meurs M et al.** Multiple sclerosis-associated CLEC16A controls HLA class II expression via late endosome biogenesis. *Brain* 2015; 38(6), 1531-1547.
 4. **Patsopoulos NA. (2016)** 200 loci complete the genetic puzzle of multiple sclerosis. In American Society of Human Genetics 2016 Annual Meeting, Vancouver, BC, Canada.
 5. **Olsson T, Barcellos LF and Alfredsson L.** Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. *Nature Reviews Neurology*. 2017; 13(1), 25.
 6. **Adorini L and Penna G.** Control of autoimmune diseases by the vitamin D endocrine system. *Nature Reviews Rheumatology* 2008; 4(8), 404.
 7. **Chun RF , Liu, PT, Modlin RL , Adams JS and Hewison, M.** Impact of vitamin D on immune function: lessons learned from genome-wide analysis. *Frontiers in physiology*. 2014;5: 151.
 8. **Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, and Pols HA.** Vitamin D receptor gene polymorphisms in relation to Vitamin D related disease states. *The Journal of steroid biochemistry and molecular biology*. 2004; 89: 187-193.
 9. **Zuvich RL , McCauley JL, Oksenberg JR, Sawcer SJ, De Jager PL, Aubin, et al.** Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. *Human genetics*. 2010; 127(5), 525-535.
 10. **cKav FC, Swain LI, Schibeci SD, Rubio JP , Kilpatrick TJ, Heard R N et al.** CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis. *Journal of autoimmunity*. 2008; 31(1): 52-58.
 11. **Koshv L . Aniu AL, Harikrishnan S , Kuttv VR , Jissa VT , Kurikesu I , et al.** Evaluating genomic DNA extraction methods from human whole blood using endpoint and real-time PCR assays. *Molecular biology reports*. 2017; 44(1) :97-108.
 12. **Dendrou, CA, Fugger L and Friese MA. (2015).** Immunopathology of multiple sclerosis. *Nature Reviews Immunology*. 2015; 15(9): 545.
 13. **Isobe N, Keshavan A, Gourraud PA, Zhu AH, Datta E, Schlaeger R et al.** Association of HLA genetic risk burden with disease phenotypes in multiple sclerosis. *JAMA neurology*. 2016; 73(7), 795-802.
 14. **Disanto G, Sandve GK , Berlanga-Taylor AJ , Ragnedda G, Morahan JM, Watson CT et al.** Vitamin D receptor binding, chromatin states and association with multiple sclerosis. *Human molecular genetics*. 2012; 21(16), 3575-3586.
 15. **Salzer J, Biström M, Sundström P.** Vitamin D and multiple sclerosis: where do we go from here?. *Expert review of neurotherapeutics*. 2014; 14 (1): 9-18.
 16. **Narooie-Nejad M, Moossavi M, Torkamanzei A, Moghtaderi A and Salimi, S.** Vitamin D receptor gene polymorphism and the risk of multiple sclerosis in South Eastern of Iran. *Journal of molecular neuroscience*. 2015;56(3) :572-576.
 17. **Sadeghi A, Shojapour M, Ghassami K and Mosayebi G.** Vitamin D Receptor Gene BsmI, FokI, ApaI, and TaqI Polymorphisms in Multiple Sclerosis Patients in Iran: A Case-Control Study. *Journal Of Iranian Clinical Research*. 2015; 1(1): 28-32.
 18. **Bermúdez-Morales VH, Fierros G, Lopez RL, Martínez-Nava G, Flores-Aldana M, Flores-Rivera J et al.** Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults. *Journal of neuroimmunology*. 2017 306: 20-24.
 19. **Agnello L, Scazzone C, Ragonese P, Salemi G, Sasso BL, Schillaci R et al. (2016).** Vitamin D receptor polymorphisms and 25-hydroxyvitamin D in a group of Sicilian multiple sclerosis patients. *Neurological Sciences*. 2016; 37(2): 261-267.
 20. **Abdollahzadeh R , Moradi Pordanjani P , Rahmani F , Mashavekhi F, Azarnezhad A and Mansoori Y (2018).** Association of VDR gene polymorphisms with risk of relapsing-remitting multiple sclerosis in an Iranian Kurdish population. *International Journal of Neuroscience*. 2018; 128(6): 505-511.
 21. **Čierny D, Michalik J, Škereňová M,**

- Kantorová E, Sivák Š, Javor J et al. (2016).** ApaI, BsmI and TaqI VDR gene polymorphisms in association with multiple sclerosis in Slovaks. *Neurological research*.2016;38(8): 678-684.
- 22.Zhang YJ, Zhang L, Chen SY, Yang GJ, Huang XL, Duan Y et al.** Association between VDR polymorphisms and multiple sclerosis: systematic review and updated meta-analysis of case-control studies. *Neurological Sciences* 2018; 39(2): 225-234.
- 23.Al-Temaimi RA, Al-Enezi A, Al-Serri A, Al-Roughani, R and Al-Mulla F.**The association of vitamin D receptor polymorphisms with multiple sclerosis in a case-control study from Kuwait. *PloS one*.2015; 10(11), e0142265.
- 24.Zhang R, Duan L , Jiang Y , Zhang X , Sun P, Li J et al. (2011).** between the IL7R T244I polymorphism and multiple sclerosis: a meta-analysis. *Molecular biology reports*.2011;38(8), 5079-5084.
- 25.Tavakolpour S.** Interleukin 7 receptor polymorphisms and the risk of multiple sclerosis: A meta-analysis. *Multiple sclerosis and related disorders*.2016; 8(5): 66-73.
- 26.Fayad L, Kherlopian A, Abdelnoor AM, Yamout B and Rahal EA.** Polymorphisms in interleukin-2 and interleukin-7 receptor α -chain genes and human herpes virus-6 as risk factors for multiple sclerosis. *Journal of Advances in Medicine and Medical Research*2014; 4 (1): 468-480.

Cite This Article

Zayed, A., Shehata, A., Gouda, T., Abd elnour, H. Association Of Vitamin D Receptor, Interleukin7 Receptor Alpha Gene Polymorphisms With The Risk Of Multiple Sclerosis. *Zagazig University Medical Journal*, 2021; (122-131): -. doi: 10.21608/zumj.2019.13593.1254